Literature DB >> 12629086

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-1 in elderly people: relationships with cardiovascular risk factors, body composition, size at birth, and childhood growth.

Eero Kajantie1, Caroline H D Fall, Markku Seppälä, Riitta Koistinen, Leo Dunkel, Hilkka Ylihärsilä, Clive Osmond, Sture Andersson, David J P Barker, Tom Forsén, Richard I G Holt, David I W Phillips, Johan Eriksson.   

Abstract

The IGF system is important in regulation of fetal and childhood growth. In later life, IGF-I and IGF-binding protein-1 (IGFBP-1) have been implicated in the pathogenesis of arteriosclerosis. They are, thus, potential candidates in explaining the link between early growth and adult cardiovascular disease. We measured fasting serum IGF-I and IGFBP-1 concentrations in 394 men and women from a cohort of 7086 individuals, born between 1924 and 1933 in Helsinki, Finland, whose weight and height were recorded at birth and from 7 to 15 yr of age. They also underwent clinical examination, including measurement of body fat using bioimpedance, blood pressure, glucose tolerance, and plasma insulin and fibrinogen concentrations. Serum IGF-I was positively correlated with fasting glucose (r = 0.10, P = 0.06) and fibrinogen (r = 0.19, P = 0.0001) concentrations and blood pressure (systolic and diastolic r = 0.10, P </= 0.05) and inversely with percentage body fat (r = -0.13, P = 0.01) and waist circumference (r = -0.11, P = 0.03). IGFBP-1 was inversely correlated with adult body mass index (BMI) (r = -0.46, P < 0.0001), fasting glucose and insulin concentrations, and blood pressure. There were correlations between the adult level of IGFBP-1 and birth weight (r = 0.11, P = 0.03) and ponderal index (weight/length(3)) at birth (r = 0.13, P = 0.01), but IGF-I was not related to birth measurements. There were interactive effects between childhood height or BMI and adult BMI on IGF-I and IGFBP-1 in adulthood. Tall height and high BMI at 7 yr were associated with low IGF-I (P = 0.03 for height and P = 0.003 for BMI) and high IGFBP-1 (P = 0.02 and P = 0.06) in adulthood but only in those subjects whose current BMI was below median. On further analysis these interactive effects were particularly strong for height in childhood and adult lean BMI (lean body mass/height(2)). Among men and women of below-average lean BMI, tall height at 7 yr was associated with low adult IGF-I (P = 0.007) and high IGFBP-1 (P = 0.0004) concentrations [interaction (7-yr height x adult lean BMI); P = 0.008 for IGF-I and 0.001 for IGFBP-1]. There is no evidence that reduced fetal growth programs IGF-I concentrations in old age. An association between small size at birth and low IGFBP-1 concentrations may in part reflect fetal programming effects on insulin resistance. Given the anabolic effects of the GH-IGF-I axis, subjects with tall height in childhood but low adult lean body mass may be at risk of late-life GH-IGF-I axis dysfunction. Prospective studies should address whether this group is susceptible to type 2 diabetes, coronary heart disease, and osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12629086     DOI: 10.1210/jc.2002-021380

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.

Authors:  Yin Cao; Katharina Nimptsch; Irene M Shui; Elizabeth A Platz; Kana Wu; Michael N Pollak; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2014-11-10       Impact factor: 7.396

2.  Acute changes in circulating hormones in older patients with impaired ventricular function undergoing on-pump coronary artery bypass grafting.

Authors:  M Maggio; G P Ceda; G De Cicco; E Cattadori; S Visioli; F Ablondi; C Beghi; T Gherli; S Basaria; G Ceresini; G Valenti; L Ferrucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

3.  Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3.

Authors:  Elizabeth M Poole; Shelley S Tworoger; Susan E Hankinson; Eva S Schernhammer; Michael N Pollak; Heather J Baer
Journal:  Am J Epidemiol       Date:  2011-08-09       Impact factor: 4.897

4.  Body composition and nutritional intake in children with chronic kidney disease.

Authors:  Rajeeb Rashid; Esther Neill; Wilma Smith; Diane King; T James Beattie; Anna Murphy; Ian J Ramage; Heather Maxwell; S Faisal Ahmed
Journal:  Pediatr Nephrol       Date:  2006-09-05       Impact factor: 3.714

Review 5.  Influence of obesity on the risk of developing colon cancer.

Authors:  E E Frezza; M S Wachtel; M Chiriva-Internati
Journal:  Gut       Date:  2005-10-20       Impact factor: 23.059

6.  Infant obesity and severe obesity growth patterns in the first two years of life.

Authors:  Lisaann S Gittner; Susan M Ludington-Hoe; Harold S Haller
Journal:  Matern Child Health J       Date:  2014-04

Review 7.  Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis.

Authors:  Masahito Shimizu; Masaya Kubota; Takuji Tanaka; Hisataka Moriwaki
Journal:  Int J Mol Sci       Date:  2012-01-05       Impact factor: 6.208

8.  Early-Life Body Adiposity and the Breast Tumor Transcriptome.

Authors:  Jun Wang; Cheng Peng; Catherine Guranich; Yujing J Heng; Gabrielle M Baker; Christopher A Rubadue; Kimberly Glass; A Heather Eliassen; Rulla M Tamimi; Kornelia Polyak; Susan Hankinson
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 11.816

9.  Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals.

Authors:  Hyeon-Sook Suh; Yungtai Lo; Namjong Choi; Scott Letendre; Sunhee C Lee
Journal:  J Neuroinflammation       Date:  2015-04-15       Impact factor: 8.322

10.  Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells.

Authors:  Ekaterina Volkova; Bridget A Robinson; Jinny Willis; Margaret J Currie; Gabi U Dachs
Journal:  Oncol Lett       Date:  2013-11-27       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.